Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).
David J. Watkins
No relevant relationships to disclose
Mark Ayers
Employment or Leadership Position - Merck
David Cunningham
Consultant or Advisory Role - Roche (U)
Research Funding - Amgen; AstraZeneca; Roche
Expert Testimony - Amgen (U)
Josep Tabernero
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Sabine Tejpar
No relevant relationships to disclose
Tae-You Kim
Research Funding - Merck
Tae Won Kim
Research Funding - Merck
Sun Young Kim
Research Funding - Merck
Jae Kyung Roh
Research Funding - Merck
Philip James Beale
Research Funding - Merck
Young Suk Park
Research Funding - Merck
Tormod Kyrre Guren
Research Funding - Merck
Andrey Loboda
Employment or Leadership Position - Merck
Michael Nebozhyn
Employment or Leadership Position - Merck
Robin Mogg
Employment or Leadership Position - Merck
Jared Lunceford
Employment or Leadership Position - Merck
Emmett V. Schmidt
Employment or Leadership Position - Merck
Holly M. Brown
Employment or Leadership Position - Merck
Stock Ownership - Merck
Sriram Sathyanarayanan
Employment or Leadership Position - Merck
David J. Mauro
Employment or Leadership Position - Merck